ASX ANNOUNCEMENT
25 May 2005
BIONOMICS’ ACQUISITION OF ILIAD CHEMICALS
• Acquisition of Iliad Chemicals to deliver advanced lead drug candidates in Bionomics’ focus areas of central nervous system (CNS) disorders and cancer.
• Integration of Bionomics’ biological expertise with Iliad’s proprietary chemistry platform and chemistry team.
• Key plank in Bionomics’ accelerated development strategy.
• Iliad Chemicals acquired for 40.9 million Bionomics shares, with potential milestone payment of a further 13.6 million shares.
• Bionomics completes A$6 million capital raising supported by Iliad shareholders.
Add to My Watchlist
What is My Watchlist?